-
Allergan Aesthetics’ Botox Secures New Indication for Masseter Muscle Protrusion in China
•
Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has announced that it has received approval for a new indication from the National Medical Products Administration (NMPA) for its Botox (botulinum toxin type A) product. The drug is now approved for the temporary improvement of significant or very significant masseter muscle…
-
AbbVie and Gilgamesh Pharmaceuticals Join Forces to Develop Psychiatric Disorder Therapies
•
AbbVie (NYSE: ABBV) has announced a partnership with US-based Gilgamesh Pharmaceuticals to develop a portfolio of next-generation therapies targeting psychiatric disorders. Under the agreement, Gilgamesh will receive an upfront payment of USD 65 million, with the potential for up to USD 1.95 billion in milestone payments and sales royalties. AbbVie…
-
AbbVie’s Rinvoq Outperforms Sanofi’s Dupixent in Moderate-to-Severe Atopic Dermatitis Trial
•
AbbVie (NYSE: ABBV) has announced positive results from a head-to-head Phase IIIb/IV clinical trial comparing its JAK inhibitor Rinvoq (upadacitinib) with Sanofi’s (NASDAQ: SNY) interleukin blocker Dupixent (dupilumab) in patients with moderate-to-severe atopic dermatitis. The trial demonstrated that Rinvoq was superior in improving eczema area and severity as well as…
-
European Commission Approves Pfizer’s Antibiotic Emblaveo for Multiple Indications
•
The European Commission (EC) has granted approval for Pfizer’s (NYSE: PFE) antibiotic Emblaveo (aztreonam + avibactam) for the treatment of complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), complicated urinary tract infections (cUTI), and infections caused by aerobic Gram-negative organisms in adults. The drug was reviewed under an accelerated assessment process…
-
AbbVie’s Rinvoq Meets Main Goal in Late-Stage Giant Cell Arteritis Trial
•
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has announced that a late-stage clinical trial for its JAK inhibitor Rinvoq (upadacitinib) in combination with corticosteroids has successfully met the primary endpoint in patients with giant cell arteritis (GCA). The study demonstrated sustained remission from week 12 through week 52. The…
-
AbbVie Partners with Medincell for Development of Long-Acting Injectable Therapies
•
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has entered into a partnership with France-based biopharmaceutical firm Medincell (EPA: MEDCL) to develop up to six long-acting injectable treatments across multiple therapeutic areas. As per the agreement, Medincell will receive an upfront payment of USD 35 million, with the potential for…
-
AbbVie’s Aquipta/Qulipta Shows Promise in Migraine Prevention Trial
•
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, last week released interim results from a Phase III open-label trial of its CGRP receptor antagonist, Aquipta/Qulipta (atogepant), for the prevention of migraines in patients with chronic or episodic migraine. The data, collected between weeks 13 to 16, indicated that the average…
-
Allergan Aesthetics Launches SKINMEDICA in China, Targeting Booming Skincare Market
•
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the market launch of its premium skincare product line, SKINMEDICA, in China. Known for its safety, efficacy, and clinical use backed by extensive medical research, SKINMEDICA is poised to offer Chinese consumers healthier and more confident skin solutions. This move…
-
AbbVie Acquires Landos Biopharma to Boost Autoimmune Disease Pipeline
•
AbbVie (NYSE: ABBV) has announced its acquisition of Landos Biopharma (NASDAQ: LABP), a biopharmaceutical company specializing in autoimmune diseases. The deal includes an upfront payment of USD 137.5 million plus a potential clinical milestone payment of USD 75 million, with the transaction expected to close in the second quarter of…
-
CNIPA Invalidates AbbVie Patents, Setting New Precedent for Pharmaceutical Disclosure
•
The China National Intellectual Property Administration (CNIPA)’s Patent Re-examination Board (PRB) has reportedly invalidated two patents associated with AbbVie (NYSE: ABBV)’s JAK inhibitor, upadacitinib, listed in China’s version of the ‘Orange Book’. This ruling, highlighted by Lusheng Law Firm’s Terry Lu, could set a critical precedent for innovative pharmaceutical companies,…
-
AbbVie Partners with OSE Immunotherapeutics to Develop First-in-Class Immunotherapy OSE-230
•
AbbVie (NYSE: ABBV) has entered into a strategic partnership with France-based OSE Immunotherapeutics (EPA: OSE) to develop the potential first-in-class immunotherapy OSE-230, which is currently in the pre-clinical stage for the treatment of chronic and severe inflammation. Under the terms of the agreement, AbbVie will acquire exclusive global rights to…
-
Alvotech Scores FDA Nod for Interchangeable High-Concentration Biosimilar to Humira
•
The US Food and Drug Administration (FDA) has granted approval to Iceland-based Alvotech’s (NASDAQ: ALVO) Simlandi, marking it as the first interchangeable high-concentration, citrate-free biosimilar to AbbVie’s (NYSE: ABBV) immunosuppressant Humira (adalimumab). Humira faced patent expiration in the US last year, leading to biosimilar competition. Simlandi is approved for various…
-
AbbVie CEO Rick González to Retire, Succeeded by Robert A. Michael
•
AbbVie (NYSE: ABBV), a leading US pharmaceutical company, has announced that Rick González, who has been at the helm since the company’s separation from Abbott (NYSE: ABT) in 2013, will retire from his role as CEO. González will transition to the position of executive chairman of the board of directors,…
-
AbbVie Expands Licensing Agreement for Innovative sCAR-T Platform with Scripps Research
•
AbbVie (NYSE: ABBV) has expanded its collaboration with Scripps Research’s Calibr-Skaggs Institute, securing licensing rights to the institute’s investigational switchable CAR-T (sCAR-T) platform, which has shown promising early-stage results. The agreement entails an upfront payment, along with potential milestone payments and royalties, allowing AbbVie to access the program for up…
-
AbbVie Reports $54.3 Billion in 2023 Revenues Amid Humira Erosion and Segment Variability
•
AbbVie (NYSE: ABBV) reported revenues of $54.3 billion for 2023, reflecting a 5.9% year-on-year decline at constant currency rates, as the company grapples with the erosion of its flagship immunosuppressant, Humira (adalimumab). While the neuroscience and aesthetics segments showed resilience with revenue increases of 18.5% and 0.9%, generating $7.7 billion…
-
AbbVie Grants Enigma Biomedical Group Rights to Next-Generation PET Imaging Biomarkers
•
AbbVie (NYSE: ABBV), a leading pharmaceutical company in the US, has licensed to Canada-based Enigma Biomedical Group (EBG) its cutting-edge F18 PET imaging biomarkers. These biomarkers are designed to detect the presence of four-repeat (4R) tau protein in patients who may have neurodegenerative diseases. The agreement holds potential for aiding…
-
Regenxbio’s One-Time Gene Therapy for Wet AMD Shows Promise in Phase II Study
•
Gene therapy specialist Regenxbio (NASDAQ: RGNX) has announced preliminary results from a Phase II study for ABBV-RGX-314, a VEGF pathway inhibitor developed in partnership with AbbVie (NYSE: ABBV) for the treatment of wet age-related macular degeneration (wet AMD). The therapy is designed to be administered as a one-time injection, aiming…
-
AbbVie’s Lutikizumab Advances to Phase III for Hidradenitis Suppurativa After Positive Mid-Stage Results
•
AbbVie (NYSE: ABBV) has announced the progression of lutikizumab to Phase III clinical trials following the IL1α/1β antagonist’s successful performance in a mid-stage trial for patients with moderate-to-severe hidradenitis suppurativa (HS) who had failed anti-TNF therapy. The study successfully met its primary endpoint, demonstrating a 35% higher clinical response rate…
-
AbbVie Launches Continuous Infusion Therapy for Advanced Parkinson’s Disease in EU
•
AbbVie (NYSE: ABBV) has announced the launch of its dopamine replacement therapy, Produodopa (foslevodopa + foscarbidopa), in the European Union (EU) for the treatment of advanced Parkinson’s disease (PD). The therapy is indicated for patients experiencing severe motor fluctuations, hyperkinesia, or dyskinesia, and when other treatments fail to adequately control…
-
AbbVie Partners with Umoja Biopharma to Develop Next-Generation CAR-T Therapies
•
AbbVie (NYSE: ABBV) has entered into a collaboration agreement with Umoja Biopharma, a US-based company specializing in next-generation in-situ CAR-T cell therapies. Under the partnership, the two companies will develop up to four programs targeting selected cancer therapies chosen by AbbVie. AbbVie has also secured an exclusive option to license…
